Icon

COBENFY (NDA216158)- (20MG;EQ 50MG BASE,20MG;EQ 100MG BASE,30MG;EQ 125MG BASE)

TROSPIUM CHLORIDE; XANOMELINE TARTRATE BRISTOL-MYERS
20MG;EQ 50MG BASE,20MG;EQ 100MG BASE,30MG;EQ 125MG BASE
No Yes
2039-Sep-27 2029-Sep-26
None None
None No
COBENFY is a combination of xanomeline, a muscarinic agonist, and trospium chloride, a muscarinic antagonist, indicated for the treatment of schizophrenia in adults.
0 0 0
Total Other Developers None
Drugs with Suitability No
20MG;EQ 50MG BASE ** ** - - -
20MG;EQ 100MG BASE ** ** - - -
30MG;EQ 125MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.